<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5398">
  <stage>Registered</stage>
  <submitdate>3/10/2014</submitdate>
  <approvaldate>3/10/2014</approvaldate>
  <nctid>NCT02258581</nctid>
  <trial_identification>
    <studytitle>Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection</studytitle>
    <scientifictitle>A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-001050-16</secondaryid>
    <secondaryid>GS-US-330-1508</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GS-4774
Treatment: drugs - GS-9620
Treatment: drugs - Tenofovir disoproxil fumarate (TDF)

Treatment: drugs: GS-4774
Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.

Treatment: drugs: GS-9620
Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.

Treatment: drugs: Tenofovir disoproxil fumarate (TDF)
Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of participants with serum hepatitis B surface antigen (HBsAg) decline = 0.5 log10 IU/ml from baseline at Week 48 - This endpoint will be measured for participants who are HBsAg positive at baseline.</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of participants who remain HBsAg negative at Week 48 - This endpoint will be measured for participants who are HBsAg negative at baseline.</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with serum HBsAg decline = 0.5 log10 IU/ml from baseline at Week 144 - This endpoint will be measured for participants who are HBsAg positive at baseline.</outcome>
      <timepoint>Week 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants who achieve HBsAg loss at Weeks 48 and 144 - This endpoint will be measured for participants who are HBsAg positive at baseline.</outcome>
      <timepoint>Weeks 48, 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants who remain HBsAg negative at Week 144 - This endpoint will be measured for participants who are HBsAg negative at baseline.</outcome>
      <timepoint>Week 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of participants with hepatitis B envelope antigen (HBeAg) loss and seroconversion at Week 48 - This endpoint will be measured for participants who are HBeAg positive at baseline.</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of participants with HBeAg loss and seroconversion at Week 144 - This endpoint will be measured for participants who are HBeAg positive at baseline.</outcome>
      <timepoint>Week 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of participants who remain HBeAg negative and hepatitis B envelope antibody (HBeAb) positive at Week 48 - This endpoint will be measured for HBeAg positive who achieved HBeAg seroconversion during the parental study.</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of participants who remain HBeAg negative and HBeAb positive at Week 144 - This endpoint will be measured for HBeAg positive who achieved HBeAg seroconversion during the parental study.</outcome>
      <timepoint>Week 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with HBV DNA &lt; the lower limit of quantitation (LLOQ) at Weeks 48, 96 and 144 - This endpoint will be measured for participants who are on treatment with oral antiviral (OAV) anti-HBV.</outcome>
      <timepoint>Weeks 48, 96 and 144</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in HBV DNA at Weeks 48, 96, and 144</outcome>
      <timepoint>Baseline; Week 48; Week 96; Week 144</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Must have participated in a Gilead-sponsored chronic hepatitis B (CHB) study no more
             than 120 days prior to Baseline (Day 1), except for participants from previous
             Gilead-sponsored study number GS-US-174-0149, who will have up to one year from their
             last visit in that protocol.

          -  Must have the ability to understand and sign a written informed consent form, which
             must be obtained prior to initiation of study procedures

          -  Must be willing and able to comply with the visit schedule and study requirements

          -  Must have documented HBV DNA &lt; 2,000 IU/mL at time of screening visit, which shall
             occur no later than 1 year post last study visit in GS-US-174-0149

          -  Must have documented hepatitis B surface antigen (HBsAg) negative status anytime
             during participation in GS-US-174-0149 regardless of ongoing HBV treatment

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient participating or planning to participate in another clinical study with an
             investigational agent

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with follow-up, assessments or compliance with the protocol

          -  Believed by the Study Investigator to be inappropriate for study participation for any
             reason not otherwise listed

          -  Received TDF monotherapy either as part of GS-US-174-0149 Arm C (TDF monotherapy arm)
             or for TDF retreatment, and have taken any HBV antiviral therapy since completion of
             GS-US-174-0149

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>9/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>241</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>14/08/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode> - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Lai Chi Kok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Sha Tin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gurarat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>West Bengal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Foggia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Parma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the
      HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only
      individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02258581</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>